Skip to Content
MilliporeSigma

D0650000

Desmopressin

European Pharmacopoeia (EP) Reference Standard

Slide 1 of 1
Sign In to View Organizational & Contract Pricing

Select a Size

1 MG

$140.00

$140.00

List Price$175.00Save 20%
Check Cart for Availability
Need it sooner? View alternative products.
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C46H64N14O12S2
CAS Number:
16679-58-6
Molecular Weight:
1069.22
MDL number:
MFCD00080163
UNSPSC Code:
41116107
NACRES:
NA.24

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

pharmaceutical primary standard

API family

desmopressin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

S1SCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C1)C(=O)N4C(CCC4)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N)Cc3ccccc3)Cc2ccc(cc2)O.OC(=O)C.O.O.O

InChI

1S/C46H64N14O12S2.C2H4O2.3H2O/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25;1-2(3)4;;;/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52);1H3,(H,3,4);3*1H2

InChI key

YNKFCNRZZPFMEX-UHFFFAOYSA-N

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
B1168000O0770000D0400000
vibrant-m

D0650000

Desmopressin

vibrant-m

B1168000

Buserelin

vibrant-m

O0770000

Oxytocin/Desmopressin validation mixture

Desoxycortone acetate European Pharmacopoeia (EP) Reference Standard

D0400000

Desoxycortone acetate

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

format

neat

format

neat

format

neat

format

neat

API family

desmopressin

API family

buserelin

API family

oxytocin, desmopressin

API family

desoxycortone

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Desmopressin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

PLEASE NOTE: TEMPORARILY UNAVAILABLE DUE TO RESTRICTED QUANTITY

related product

Product No.
Description
Pricing

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Patrina Hy Caldwell et al.
The Cochrane database of systematic reviews, 5, CD002911-CD002911 (2020-05-05)
Enuresis (bedwetting) affects up to 20% of five-year-olds and can have considerable social, emotional and psychological effects. Treatments include alarms (activated by urination), behavioural interventions and drugs. To assess the effects of enuresis alarms for treating enuresis in children. We
Peter K Sand et al.
The Journal of urology, 190(3), 958-964 (2013-03-05)
Previous studies suggest a lower dose of desmopressin orally disintegrating tablet may be effective in females compared to males with nocturia. We confirm the efficacy and safety of 25 μg desmopressin orally disintegrating tablet compared to placebo in female patients.
Jeffrey P Weiss et al.
The Journal of urology, 190(3), 965-972 (2013-03-05)
We investigated the efficacy and safety of 50 and 75 μg desmopressin orally disintegrating tablets in men with nocturia (2 or more nocturnal voids). In this 3-month, randomized, double-blind, parallel study 50 and 75 μg desmopressin were compared with placebo.
D A Vassiliadi et al.
The Journal of clinical endocrinology and metabolism, 101(12), 4878-4885 (2016-09-24)
Cushing's disease (CD) has a significant relapse rate after successful transsphenoidal surgery (TSS). Many CD patients respond aberrantly to the desmopressin test (DT). Disappearance of this response after surgery may suggest complete removal of abnormal corticotrophs and a lower possibility
Yutaka Oiso et al.
The Journal of clinical endocrinology and metabolism, 98(10), 3958-3967 (2013-07-26)
In recent years, there have been several improvements in the treatment of neurohypophyseal diabetes insipidus (DI). They include new formulations of the vasopressin analog, desmopressin; a better understanding of the effect of fluid intake on dosing; and more information about
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service